Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
-
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
r
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid + NAD+
(5Z,8E,10E)-12-oxo-5,8,10-heptadecatrienoic acid + NADH
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
15(S)-hydroperoxy-5,8,11,13-(Z,Z,Z,E)-eicosatetraenoic acid + NAD+
15-oxo-5,8,11,13-(Z,Z,Z,E)-eicosatetraenoic acid + NADH
-
-
-
-
?
15-hydroxyeicosatetraenoic acid + NAD+
15-ketoeicosatetraenoic acid + NADH
-
-
-
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
19-hydroxyprostaglandin E1 + NAD+
19-hydroxy-15-oxoprostaglandin E1 + NADH
-
-
-
?
20-hydroxyprostaglandin E1 + NAD+
20-hydroxy-15-ketoprostaglandin E1 + NADH
-
-
-
?
5,6-chrysenequinone + NADH
?
-
-
-
-
?
5,6-chrysenequinone + NADH
? + H2O2
-
formation of potentially hazardous semiquinones, reaction mechanism, overview
-
-
?
6-keto-prostaglandin E1 + NAD+
? + NADH
-
-
-
-
?
6-keto-prostaglandin F1alpha + NAD+
? + NADH
-
-
-
-
?
6-ketoprostaglandin E1 + NAD+
6,15-diketoprostaglandin E1
-
-
-
?
6-ketoprostaglandin F1alpha + NAD+
6,15-diketoprostaglandin F1alpha + NADH + H+
9,10-phenanthrenequinone + NADH
?
-
-
-
-
?
9,10-phenanthrenequinone + NADH
? + H2O2
-
formation of potentially hazardous semiquinones, reaction mechanism, overview
-
-
?
prostaglandin A1 + NAD+
15-ketoprostaglandin A1 + NADH + H+
prostaglandin A1 + NAD+
? + NADH
-
-
-
-
?
prostaglandin A2 + NAD+
15-ketoprostaglandin A2 + NADH + H+
prostaglandin D1 + NAD+
15-ketoprostaglandin D1 + NADH + H+
-
very low activity
-
?
prostaglandin D2 + NAD+
15-ketoprostaglandin D2 + NADH + H+
prostaglandin D2 + NAD+
? + NADH
-
-
-
-
?
prostaglandin E1 + NAD+
15-ketoprostaglandin E1 + NADH + H+
-
-
-
-
?
prostaglandin E1 + NAD+
15-oxoprostaglandin E1 + NADH + H+
-
-
-
-
r
prostaglandin E1 + NAD+
? + NADH
-
-
-
-
?
prostaglandin E2 + NAD+
15-ketoprostaglandin E2 + NADH + H+
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
prostaglandin E3 + NAD+
15-keto-prostaglandin E3 + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
prostaglandin F2alpha + NAD+
15-oxoprostaglandin F2alpha + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
? + NADH
-
-
-
-
?
prostaglandin I2 + NAD+
15-ketoprostaglandin I2 + NADH + H+
-
-
-
?
additional information
?
-
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
r
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. prostaglandin E1
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. prostaglandin E1
i.e. 15-ketoprostaglandin E1
r
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
catabolism of (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglnadin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
key step in prostaglandin catabolism, enzyme activation leads to reduced cell proliferation, the enzyme is an antagonist of ibuprofen
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
key step in prostaglandin inactivation
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
PGE2 degradation
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
prostaglandin E2, PGE2, a proinflammatory bioactive lipid, promotes cancer progression by modulating proliferation, apoptosis, and angiogenesis, PGE2 is a downstream product cyclooxygenase and is biochemically inactivated by the enzyme
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells, overview
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
the enzyme is a putative cyclooxygenase-2 antagonist and and tumor suppressor
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
transcriptional regulation and biological functions, the enzyme cooperates with cyclooxygenase-2 to control cellular prostaglandin levels, reciprocal regulation of the two enzymes, overview
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2, inactivation
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2, substrate binding structure analysis, determination of interactions
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
PGE2 degradation
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2, best substrate
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
the enzyme catalyzes the oxidation of the 15(S)-hydroxyl group of prostaglandin E2 (PGE2), converting the proinflammatory PGE2 to the anti-inflammatory 15-keto-PGE2 (an endogenous ligand for peroxisome proliferator-activated receptor-gamma [PPAR-gamma])
-
-
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid + NAD+
(5Z,8E,10E)-12-oxo-5,8,10-heptadecatrienoic acid + NADH
-
-
-
?
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid + NAD+
(5Z,8E,10E)-12-oxo-5,8,10-heptadecatrienoic acid + NADH
-
-
-
?
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid + NAD+
(5Z,8E,10E)-12-oxo-5,8,10-heptadecatrienoic acid + NADH
-
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
NAD+ is much more effective than NADP+
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
specific for NAD+
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
specific for NAD+
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
specific for NAD+
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
NADP+ is more effective than NAD+
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
-
-
-
-
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
-
physiological inactivation of prostaglandin by catalyzing the first step in catabolism
-
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
-
physiological inactivation of prostaglandin by catalyzing the first step in catabolism
-
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
-
physiological inactivation of prostaglandin by catalyzing the first step in catabolism
-
?
6-ketoprostaglandin F1alpha + NAD+
6,15-diketoprostaglandin F1alpha + NADH + H+
-
-
-
?
6-ketoprostaglandin F1alpha + NAD+
6,15-diketoprostaglandin F1alpha + NADH + H+
-
-
-
?
prostaglandin A1 + NAD+
15-ketoprostaglandin A1 + NADH + H+
-
-
-
?
prostaglandin A1 + NAD+
15-ketoprostaglandin A1 + NADH + H+
-
-
-
?
prostaglandin A1 + NAD+
15-ketoprostaglandin A1 + NADH + H+
-
-
-
?
prostaglandin A1 + NAD+
15-ketoprostaglandin A1 + NADH + H+
-
-
-
-
?
prostaglandin A1 + NAD+
15-ketoprostaglandin A1 + NADH + H+
-
-
-
?
prostaglandin A1 + NAD+
15-ketoprostaglandin A1 + NADH + H+
-
-
-
?
prostaglandin A1 + NAD+
15-ketoprostaglandin A1 + NADH + H+
-
-
-
?
prostaglandin A2 + NAD+
15-ketoprostaglandin A2 + NADH + H+
-
-
-
?
prostaglandin A2 + NAD+
15-ketoprostaglandin A2 + NADH + H+
-
-
-
-
?
prostaglandin D2 + NAD+
15-ketoprostaglandin D2 + NADH + H+
-
-
-
?
prostaglandin D2 + NAD+
15-ketoprostaglandin D2 + NADH + H+
-
-
-
?
prostaglandin E2 + NAD+
15-ketoprostaglandin E2 + NADH + H+
-
-
-
-
?
prostaglandin E2 + NAD+
15-ketoprostaglandin E2 + NADH + H+
-
the wild type enzyme is highly active against prostaglandin E2 and NAD+
-
-
?
prostaglandin E2 + NAD+
15-ketoprostaglandin E2 + NADH + H+
-
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
-
r
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
NAD+ is much more effective than NADP+
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
specific for NAD+
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
specific for NAD+
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
specific for NAD+
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
NADP+ is more effective than NAD+
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
?
additional information
?
-
-
the enzyme catalyzes specifically the oxidation of the (15S)-hydroxy group of all natural prostaglandins except the B and 19-hydroxylated types
-
-
?
additional information
?
-
-
dexamethasone and phorbol ester play a role in enzyme regulation in erythroleukemia cells
-
-
?
additional information
?
-
-
key enzyme for metabolic inactivation of prostaglandins, enzyme levels are reduced in inflammatory bowel disease involving TNF-alpha
-
-
?
additional information
?
-
-
the enzyme is a tumor suppressor of human breast cancer, expression of the enzyme and the estrogen receptor is correlated, silencing of the enzyme results in enhanced cancer cell proliferation, the enzyme expression is silenced in vivo in cancer cells due to promoter methylation
-
-
?
additional information
?
-
-
the enzyme is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a medullary thyroid carcinoma cell line
-
-
?
additional information
?
-
-
15-hydroxyprostaglandin dehydrogenase may be repressed by an epigenetic mechanism involving histone deacetylation, resulting in increased prostaglandin E2 activity in tumors
-
-
?
additional information
?
-
-
prostaglandins play an essential role in primate parturition acting on uterine contractility and on cervical ripening
-
-
?
additional information
?
-
-
the enzyme is an in vivo suppressor of colon tumorigenesis, mechanism of conferring increased susceptibility to colon neoplasia, overview
-
-
?
additional information
?
-
-
the enzyme is an in vivo suppressor of colon tumorigenesis, mechanism of conferring increased susceptibility to colon neoplasia, overview
-
-
?
additional information
?
-
-
substrate specificity, overview, no activity with prostaglandin B1
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
-
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
r
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
additional information
?
-
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
r
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
catabolism of (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglnadin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
key step in prostaglandin catabolism, enzyme activation leads to reduced cell proliferation, the enzyme is an antagonist of ibuprofen
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
key step in prostaglandin inactivation
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
PGE2 degradation
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
prostaglandin E2, PGE2, a proinflammatory bioactive lipid, promotes cancer progression by modulating proliferation, apoptosis, and angiogenesis, PGE2 is a downstream product cyclooxygenase and is biochemically inactivated by the enzyme
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells, overview
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
the enzyme is a putative cyclooxygenase-2 antagonist and and tumor suppressor
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
transcriptional regulation and biological functions, the enzyme cooperates with cyclooxygenase-2 to control cellular prostaglandin levels, reciprocal regulation of the two enzymes, overview
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
PGE2 degradation
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
the enzyme catalyzes the oxidation of the 15(S)-hydroxyl group of prostaglandin E2 (PGE2), converting the proinflammatory PGE2 to the anti-inflammatory 15-keto-PGE2 (an endogenous ligand for peroxisome proliferator-activated receptor-gamma [PPAR-gamma])
-
-
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
-
physiological inactivation of prostaglandin by catalyzing the first step in catabolism
-
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
-
physiological inactivation of prostaglandin by catalyzing the first step in catabolism
-
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
-
physiological inactivation of prostaglandin by catalyzing the first step in catabolism
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
-
?
additional information
?
-
-
dexamethasone and phorbol ester play a role in enzyme regulation in erythroleukemia cells
-
-
?
additional information
?
-
-
key enzyme for metabolic inactivation of prostaglandins, enzyme levels are reduced in inflammatory bowel disease involving TNF-alpha
-
-
?
additional information
?
-
-
the enzyme is a tumor suppressor of human breast cancer, expression of the enzyme and the estrogen receptor is correlated, silencing of the enzyme results in enhanced cancer cell proliferation, the enzyme expression is silenced in vivo in cancer cells due to promoter methylation
-
-
?
additional information
?
-
-
the enzyme is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a medullary thyroid carcinoma cell line
-
-
?
additional information
?
-
-
15-hydroxyprostaglandin dehydrogenase may be repressed by an epigenetic mechanism involving histone deacetylation, resulting in increased prostaglandin E2 activity in tumors
-
-
?
additional information
?
-
-
prostaglandins play an essential role in primate parturition acting on uterine contractility and on cervical ripening
-
-
?
additional information
?
-
-
the enzyme is an in vivo suppressor of colon tumorigenesis, mechanism of conferring increased susceptibility to colon neoplasia, overview
-
-
?
additional information
?
-
-
the enzyme is an in vivo suppressor of colon tumorigenesis, mechanism of conferring increased susceptibility to colon neoplasia, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1-butyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
-
(1-phenyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
-
(1-tert-butyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
-
(3,3-dimethylpiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
-
(3,5-dimethylpiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
-
(4-([(4-chlorophenyl)sulfanyl]methyl)phenyl)(4-methylpiperidin-1-yl)methanone
-
-
(4-bromopiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
-
(4-[(2-bromophenoxy)methyl]phenyl)(piperidin-1-yl)methanone
-
-
(5Z)-5-[3-bromo-4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(3-cyclohexylpropoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(4-cyclohexylbutoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(cyclohexylmethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(cyclohexyloxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[4-(2-cyclohexylethoxy)-3-methoxybenzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[4-(2-cyclohexylethoxy)-3-methoxybenzylidene]-3-methyl-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(9Z,12E)-13-hydroxyoctadeca-9,12-dienoic acid
-
0.01 mM, 45% inhibition
(piperidin-1-yl)[1-[3-(propan-2-yl)phenyl]-1H-benzimidazol-5-yl]methanone
-
(piperidin-1-yl)[1-[3-(trifluoromethyl)phenyl]-1H-benzimidazol-5-yl]methanone
-
(piperidin-1-yl)[1-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-5-yl]methanone
-
1,2-naphthoquinone
-
0.0002 mM, time dependent inactivation, 1 mM glutathione or 40% glycerol protect from inactivation; inactivation, glutathione protects
12-O-tetradecanoylphorbol-13-acetate
-
10 nM, rapid loss of activity in eryrthroleukemia cells during 40 min, inhibition can be prevented by staurosporin indicating that protein kinase C is involved; induces the synthesis of 15-PGDH but inhibits the enzyme activity a protein kinase C mediated mechanism
13-cis-Prostaglandin F2alpha
-
0.124 mM, 50% inhibition
13-hydroxyperoxyoctadecadienoic acid
-
0.001 mM to 0.01 mM, 50% inhibition with 0.003 mM, uncompetitive inhibition vs. NAD+, noncompetitive vs. prostaglandin E2
15-deoxy-DELTA12,14-prostaglandin J2
-
0.024 mM, 50% inhibition
15-epi-prostaglandin E1
-
-
15-Epiprostaglandin E1
-
0.17 mM, 50% inhibition
15-ketoprostaglandin E1
-
-
15-ketoprostaglandin E2
-
-
2,4,6-Trinitrobenzenesulfonic acid
-
-
2-([(6-bromo-4H-imidazo[4,5-b]pyridin-2-yl)sulfanyl]methyl)benzonitrile
-
-
2-azido NAD+
-
photoaffinity analog of NAD+, 0.115 mM, complete inactivation
2-hydroxy-5-(3,5-dimethoxycarbonyl-benzoyl)-benzene acetic acid
2-methyl-1,4-naphthoquinone
-
0.02 mM, time dependent inactivation
2-[[(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)sulfanyl]methyl]benzonitrile
-
3,3',5-triiodothyronine
-
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-5,6,7,8,9,10-hexahydro[1,2,4]triazolo[4,3-a]azocine
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9,10,11-hexahydro-5H-[1,2,4]triazolo[4,3-a]azonine
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]azepine
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole
-
3-[1-(3,4-dichlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[1-(3-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[1-(4-bromophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[1-(4-methoxyphenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[1-(4-tert-butylphenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-(4-methylphenyl)-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-(4-nitrophenyl)-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-[4-(naphthalen-2-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-[4-(pyridin-2-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-[4-(pyridin-3-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-[4-(pyridin-4-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzonitrile
-
4,5-benzo[a]pyrenequinone
-
0.0002 mM, time dependent inactivation
4-((2,5-dioxopyrrolidin-3-ylidene)methyl)phenylthiophene-2-carboxylate
-
4-chloromercuriphenylsulfonic acid
-
-
4-methoxybenzyl-2,4-thiazolidinedione
-
-
4-methoxybenzylidene-2,4-thiazolidinedione
-
-
4-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzonitrile
-
5-(2-chloro-3-(2-(pyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(2-chloro-4-(2-(cyclohexyloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(2-chloro-4-(2-(propan-2-yloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(2-chloro-4-(2-cyclohexylethoxy)benzylidene)-thiazolidine-2,4-dione
-
5-(2-chloro-4-(2-cyclopentylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(2-chloro-4-(4-nitrobenzyloxy)benzylidene)thiazolidine-2,4-dione
-
5-(2-chloro-4-phenbutoxybenzylidene)thiazolidine-2,4-dione
-
5-(2-chloro-4-phenethoxybenzylidene)thiazolidine-2,4-dione
-
5-(2-chloro-4-phenpropoxybenzylidene)thiazolidine-2,4-dione
-
5-(3-chloro-4-((4-(prop-1-en-2-yl)cyclohexyl)methoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-((5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)oxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-(4-methyl-1,3-thiazolidin-5-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-(5-ethylpyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-(5-nitrofuran-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-(cyclohexyloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-(propan-2-yloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-(pyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-(thiophen-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-cyclopentylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-cyclopropylpropyl)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-thiomorpholine 1,1-dioxideethoxy)benzylidene)thiazolidine-2,4-dione
-
5-(3-chloro-4-(3-(2-nitroethenyl)phenoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(3-nitrophenoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(3-phenylpropoxy)benzylidene)thiazolidine-2,4-dione
-
5-(3-chloro-4-(4-nitrobenzyloxy)benzylidene)thiazolidine-2,4-dione
-
5-(3-chloro-4-(4-phenylbutoxy)benzylidene)thiazolidine-2,4-dione
-
5-(3-chloro-4-(cyclobutylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(cyclopentylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-phenylethoxybenzylidene)thiazolidine-2,4-dione
-
5-(4-((4-methylcyclohexyl)methoxy)benzylidene) thiazolidine-2,4-dione
-
-
5-(4-(1,3-benzodioxol-5-ylmethoxy)-3-chlorobenzylidene)-1,3-thiazolidine-2,4-dione
-
5-(4-(2-(thiophen-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(4-(2-(thiophen-3-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(4-(2-cyclopentylethoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(4-(4-(chloromethyl)benzyloxy)benzylidene) thiazolidine-2,4-dione
-
-
5-(4-(benzyloxy)-2-chlorobenzylidene)thiazolidine-2,4-dione
-
5-(4-(benzyloxy)-3-chlorobenzylidene)thiazolidine-2,4-dione
-
5-(4-(bicyclo[2.2.1]hept-2-ylmethoxy)-3-chlorobenzylidene)-1,3-thiazolidine-2,4-dione
-
5-(4-(cyclopentylmethoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-[4-((1-methyl)-cyclohexylmethoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-((1-methyl)-cyclohexylmethoxy)benzyl]-2,4-thiazolidenedione
-
trivial name ciglitazone
5-[4-(benzoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexylbutoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexylethoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexylmethoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexyloxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexylpropoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[[4-(ethoxycarbonyl)phenyl]azo]-2-hydroxy-benzeneacetic acid
-
CAY-10397, specific 15-PGDH inhibitor
5-[[4-(ethoxycarbonyl)phenyl]azo]2-hydroxy-benzene acetic acid
CAY-10397
7,8-benzo[a]pyrenequinone
-
0.0002 mM, time dependent inactivation, 40% glycerol protects from inactivation; inactivation, glutathione protects
7-Oxa-13-prostynoic acid
-
0.0475 mM, 50% inhibition
7-oxa-prostanoic acid
-
-
7-Thia-13-prostynoic acid
-
0.0068 mM, 50% inhibition
7-thia-prostanoic acid
-
-
acrolein
-
irreversible inhibition
adenosine-5'-diphosphoribose
-
-
Berberine
-
0.023 mM, 50% inhibition
Biochanin A
-
0.031 mM, 50% inhibition
CAY 10397
-
specific inhibitor, completely reverses the stimulating effect of ibuprofen on cell proliferation in TT cells
chalcone
-
0.016 mM, 50% inhibition
chrysin
-
0.021 mM, 50% inhibition
Cu2+
-
0.05 mM to 0.5 mM, 50% inhibition with 0.1 mM, uncompetitive vs. NAD+, non-competitive vs. prostaglandin E2
curcumin
-
0.01 mM, 50% inhibition
DuP 697
-
0.022 mM, 50% inhibition
ent-13-dehydro-15-epi-prostaglandin F2alpha
-
-
Ent-13-dehydro-15-epiprostaglandin F3alpha
-
0.055 mM, 50% inhibition
ent-13-dehydroprostaglandin E2
-
0.0068 mM, 50% inhibition
epi-7-thia-prostaglandin F2alpha
-
-
epi-7-thiaprostaglandin F2alpha
-
0.0052 mM, 50% inhibition
epigallocatechin gallate
-
0.012 mM, 50% inhibition
ethyl 4-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzoate
-
Flufenamic acid
-
0.041 mM, 50% inhibition
flurbiprofen
-
0.062 mM, 50% inhibition
glycerol
-
slight inhibition
hexadecanoic acid
-
0.01 mM
ketorolac
-
0.028 mM, 50% inhibition
linoleic acid
-
0.01 mM, 30% inhibition
Meclofenamic acid
-
0.073 mM, 50% inhibition
Mefenamic acid
-
0.076 mM, 50% inhibition
mixture of endogenous fatty acids
-
mixture contains palmitic acid, stearic acid linoleic acid and oleic acid, competitive vs. prostaglandine E2
-
MK 886
-
0.037 mM, 50% inhibition
N,N-diethyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
-
N-(2-phenylethyl)-indomethacin amide
-
0.098 mM, 50% inhibition
N-(3-pyridyl)-indomethacin amide
-
0.1 mM, 50% inhibition
N-butyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
-
N-cyclopentyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
-
nat-13-dehydroprostaglandin E2
-
-
nat-13-dehydroprostaglandin F3alpha
-
-
Nat-13-thiaprostaglandin F2alpha
-
0.0088 mM, 50% inhibition
-
nat-7-thia-prostaglandin F2alpha
-
-
nat-l3-dehydroprostaglandin F2alpha
-
-
niflumic acid
-
0.058 mM, 50% inhibition
nimesulide
-
0.051 mM, 50% inhibition
NS 398
-
0.064 mM, 50% inhibition
octadecanoic acid
-
0.01 mM
p-chloromercuriphenylsulfonic acid
-
-
PD 98059
-
an ERK kinase inhibitor
prostaglandin F2alpha
-
-
pyridoxal 5'-phosphate
-
-
resveratrol
-
0.054 mM, 50% inhibition
sulindac
-
0.041 mM, 50% inhibition
sulindac sulfide
-
0.018 mM, 50% inhibition
sulindac sulfone
-
0.038 mM, 50% inhibition
tetradecanoic acid
-
0.01 mM
Tetraiodothyroacetic acid
-
-
Zn2+
-
0.05 mM to 0.5 mM, 50% inhibition with 0.15 mM, uncompetitive vs. NAD+, non-competitive vs. prostaglandin E2
[1-(2-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[1-(3-chlorophenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[1-(3-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](3-methylpiperidin-1-yl)methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](3-phenylpiperidin-1-yl)methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](4-methylpiperazin-1-yl)methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](morpholin-4-yl)methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](pyrrolidin-1-yl)methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][3-(propan-2-yl)piperidin-1-yl]methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][3-(trifluoromethyl)piperidin-1-yl]methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][4-(trifluoromethyl)piperidin-1-yl]methanone
-
[1-(3-tert-butylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[1-(4-chlorophenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[1-(4-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[1-(4-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[1-(4-tert-butylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[4-(4-methoxyphenyl)piperazin-1-yl](4-[(phenylsulfanyl)methyl]phenyl)methanone
-
-
2-hydroxy-5-(3,5-dimethoxycarbonyl-benzoyl)-benzene acetic acid
-
1000 times more potent inhibitor than sulfaphasalazine
2-hydroxy-5-(3,5-dimethoxycarbonyl-benzoyl)-benzene acetic acid
-
1000 times more potent inhibitor than sulfaphasalazine
arachidonic acid
-
0.0027 mM, 50% inhibition; irreversible inactivation
ciglitazone
-
-
ciglitazone
-
0.003 mM, 50% inhibition
Ethacrynic acid
-
0.0055 mM, 50% inhibition; irreversible inactivation
ethanol
-
slight inhibition
indomethacin
-
-
indomethacin
-
0.066 mM, 50% inhibition
N-ethylmaleimide
-
-
NAD+
-
-
NAD+
-
product inhibition
NADH
-
-
NADPH
-
-
papaverine
-
the inhibition is noncompetitive with prostaglandin E2, uncompetitive with NAD+, and reversible
papaverine
-
the inhibition is noncompetitive with prostaglandin E2, uncompetitive with NAD+, and reversible
papaverine
-
the inhibition is noncompetitive with prostaglandin E2, uncompetitive with NAD+, and reversible
papaverine
-
the inhibition is noncompetitive with prostaglandin E2, uncompetitive with NAD+, and reversible
Prostaglandin B1
-
0.0497 mM, 50% inhibition
prostaglandin E2
-
-
prostaglandin E2
-
product inhibition
Prostanoic acid
-
0.013 mM, 50% inhibition
rosiglitazone
-
-
rosiglitazone
-
0.026 mM, 50% inhibition
sulphasalazine
-
anticolitic drug
sulphasalazine
-
anticolitic drug
thyroxine
-
-
troglitazone
-
-
troglitazone
-
0.34 mM, 50% inhibition
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
additional information
-
no inhibition by Ca2+
-
additional information
-
not inhibited by L-thyronine and NADH
-
additional information
-
-
-
additional information
-
IC50 values at pH 7.0 and at pH 9.0; pH-dependent inhibition and inhibition mechanism, at high substrate concentrations there is formation of unreactive complexes between the 15-hydroxyrostaglandin and both the free enzyme and enzyme-NADH complex and between the 15-ketoprostaglandin and both the free enzyme and enzyme NAD+ complex
-
additional information
-
not inhibitited by iodoacetimide
-
additional information
-
TNF-alpha suppresses the enzyme expression in colonocytes
-
additional information
-
histone deacetylase inhibitors, such as sodium butyrate, scriptaid, apicidin, and oxamflatin, and transforming growth factor-beta, TGF-beta1, induce enzyme expression in lung adenocarcinoma cells, overview
-
additional information
-
the enzyme expression is suppressed by the epidermal growth factor via snail which interacts through its zinc finger structure, mechanism overview
-
additional information
-
enzyme down-regulation by estrogen
-
additional information
-
interleukin-1beta suppresses the enzyme expression, as well as down-regulation of cyclooxygenase-2 expression, whereas down-regulation of cyclooxygenase-1 has no effect on 15-PGDH expression, overview
-
additional information
-
bile acids activate the signal transduction pathway protein kinase C-> extracellular signal-regulated kinase 1/2-> early growth response factor-1-> Snail and thereby suppress 15-PGDH transcription, unconjugated bile acids are much more potent inhibitors of 15-PGDH expression and activity than related conjugated bile acids, chenodeoxycholate and deoxycholate suppress the transcription of 15-PGDH resulting in reduced amounts of mRNA, protein, and enzyme activity
-
additional information
-
histone deacetylase 2 and the transcriptional regulator Snail play a central role in the suppression of 15-PGDH expression
-
additional information
-
not inhibited by 10 mM to 80 mM ethanol
-
additional information
-
not inhibited by thyroid hormones and NADPH
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0012 - 0.026
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
0.00765 - 0.012
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid
0.016
15-hydroxyeicosatetraenoic acid
-
-
0.0521
15-ketoprostaglandin E1
-
at pH 7.0
0.0266 - 0.0528
15-ketoprostaglandin E2
0.077
19-hydroxyprostaglandin E1
-
-
0.283
20-hydroxyprostaglandin E1
-
-
0.066
6-ketoprostaglandin E1
-
-
0.111
6-ketoprostaglandin F1alpha
-
-
0.063
6-oxo-prostaglandin F1alpha
-
recombinant enzyme expressed in E. coli
0.0045 - 0.038
prostaglandin A1
0.003 - 0.022
Prostaglandin A2
0.741
Prostaglandin D2
-
-
0.0013 - 0.033
prostaglandin E1
0.00158 - 0.059
prostaglandin E2
0.077
prostaglandin E3
-
-
0.0213 - 0.133
prostaglandin F2alpha
additional information
additional information
-
Michaelis-Menten kinetics, overview
-
0.0012
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, I17L mutant
0.0026
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, N91D mutant
0.0034
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5
0.0035
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, V186K mutant
0.0039
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
-
0.0045
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, V186A mutant
0.006
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, N91A mutant
0.0063
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5
0.0071
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5
0.0086
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, T11S mutant
0.01
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
pH 7.4, 37°C
0.011
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, I17A mutant
0.011
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, I17V mutant
0.013
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, Q15K/W37K double mutant
0.022
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, V186I mutant
0.026
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, Q15K mutant
0.00765
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid
-
-
0.012
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid
-
-
0.0266
15-ketoprostaglandin E2
-
at pH 9.0
0.0528
15-ketoprostaglandin E2
-
at pH 7.0
0.022
NAD+
-
recombinant enzyme expressed in E. coli
0.022
NAD+
-
37°C, pH 7.5, V186K mutant
0.0227
NAD+
-
at pH 9.0, + prostaglandin E2
0.024
NAD+
-
37°C, pH 7.5, V186A mutant
0.0284
NAD+
-
at pH 7.0, + prostaglandin E2
0.029
NAD+
-
at pH 9.0, + prostaglandin E1
0.0308
NAD+
-
at pH 7.0, + prostaglandin E1
0.032
NAD+
-
37°C, pH 7.5
0.032
NAD+
-
37°C, pH 7.5, N91D mutant
0.038
NAD+
-
37°C, pH 7.5
0.0399
NAD+
-
+ prostaglandin F2alpha
0.0405
NAD+
-
+ prostaglandin E2
0.0451
NAD+
-
+ prostaglandin E1
0.059
NAD+
-
37°C, pH 7.5, I17L mutant
0.098
NAD+
-
37°C, pH 7.5, I17V mutant
0.27
NAD+
-
37°C, pH 7.5, V186I mutant
0.55
NAD+
-
37°C, pH 7.5, I17A mutant
0.7
NAD+
-
37°C, pH 7.5, T11S mutant
0.72
NAD+
-
37°C, pH 7.5, N91A mutant
0.0156
NADH
-
at pH 7.0, + 15-keto-PGE1
0.0156
NADH
-
at pH 7.0, + 15-ketoprostaglandin E2
0.0594
NADH
-
at pH 9.0, + 15-ketoprostaglandin E2
0.0045
prostaglandin A1
-
recombinant enzyme expressed in E. coli
0.033
prostaglandin A1
-
-
0.038
prostaglandin A1
-
-
0.003
Prostaglandin A2
-
-
0.022
Prostaglandin A2
-
recombinant enzyme expressed in E. coli
0.0013
prostaglandin E1
-
-
0.0013
prostaglandin E1
-
at pH 7.0
0.0034
prostaglandin E1
-
-
0.0048
prostaglandin E1
-
-
0.0048
prostaglandin E1
-
at pH 9.0
0.005
prostaglandin E1
-
recombinant enzyme expressed in E. coli
0.0054
prostaglandin E1
-
-
0.027
prostaglandin E1
-
-
0.033
prostaglandin E1
-
-
0.033
prostaglandin E1
-
pH 10.2
0.00158
prostaglandin E2
-
-
0.0025
prostaglandin E2
-
at pH 7.0
0.0026
prostaglandin E2
-
-
0.0028
prostaglandin E2
-
at pH 9.0
0.0028
prostaglandin E2
-
pH 8.0, 25°C, 20 nM [1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
0.0037
prostaglandin E2
-
pH 8.0, 25°C, 10 nM [1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
0.0039
prostaglandin E2
-
recombinant enzyme expressed in E. coli
0.0055
prostaglandin E2
-
pH 8.0, 25°C
0.0056
prostaglandin E2
-
pH 8.0, 25°C, 4 nM 3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
0.0064
prostaglandin E2
-
pH 8.0, 25°C, 10 nM 3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
0.0075
prostaglandin E2
-
pH 8.0, 25°C, 10 nM 2-([(6-bromo-4H-imidazo[4,5-b]pyridin-2-yl)sulfanyl]methyl)benzonitrile
0.01
prostaglandin E2
-
-
0.0117
prostaglandin E2
-
-
0.0135
prostaglandin E2
-
pH 8.0, 25°C, 10 nM 2-([(6-bromo-4H-imidazo[4,5-b]pyridin-2-yl)sulfanyl]methyl)benzonitrile
0.014
prostaglandin E2
-
-
0.059
prostaglandin E2
-
-
0.059
prostaglandin E2
-
pH 10.2
0.0213
prostaglandin F2alpha
-
-
0.025
prostaglandin F2alpha
-
-
0.04
prostaglandin F2alpha
-
recombinant enzyme expressed in E. coli
0.059
prostaglandin F2alpha
-
-
0.133
prostaglandin F2alpha
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.000068
(1-butyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000022
(1-phenyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000034
(1-tert-butyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000068
(3,3-dimethylpiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.000271
(3,5-dimethylpiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.000631
(4-([(4-chlorophenyl)sulfanyl]methyl)phenyl)(4-methylpiperidin-1-yl)methanone
Homo sapiens
-
pH 8, 25°C
0.000076
(4-bromopiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.000089
(4-[(2-bromophenoxy)methyl]phenyl)(piperidin-1-yl)methanone
Homo sapiens
-
pH 8, 25°C
0.000019
(5Z)-5-[3-bromo-4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000008
(5Z)-5-[3-chloro-4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.00001
(5Z)-5-[3-chloro-4-(3-cyclohexylpropoxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000024
(5Z)-5-[3-chloro-4-(4-cyclohexylbutoxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000028
(5Z)-5-[3-chloro-4-(cyclohexylmethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000047
(5Z)-5-[3-chloro-4-(cyclohexyloxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
(5Z)-5-[4-(2-cyclohexylethoxy)-3-methoxybenzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.05
(5Z)-5-[4-(2-cyclohexylethoxy)-3-methoxybenzylidene]-3-methyl-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000051
(5Z)-5-[4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000068
(piperidin-1-yl)[1-[3-(propan-2-yl)phenyl]-1H-benzimidazol-5-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.000048
(piperidin-1-yl)[1-[3-(trifluoromethyl)phenyl]-1H-benzimidazol-5-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.00086
(piperidin-1-yl)[1-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-5-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.000141
2-([(6-bromo-4H-imidazo[4,5-b]pyridin-2-yl)sulfanyl]methyl)benzonitrile
Homo sapiens
-
pH 8, 25°C
0.000242
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-5,6,7,8,9,10-hexahydro[1,2,4]triazolo[4,3-a]azocine
Homo sapiens
pH and temperature not specified in the publication
0.000192
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine
Homo sapiens
pH and temperature not specified in the publication
0.000383
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9,10,11-hexahydro-5H-[1,2,4]triazolo[4,3-a]azonine
Homo sapiens
pH and temperature not specified in the publication
0.000054
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.00089
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
-
pH 8, 25°C
0.00304
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole
Homo sapiens
pH and temperature not specified in the publication
0.000022
3-[1-(3,4-dichlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000034
3-[1-(3-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000048
3-[1-(4-bromophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000038
3-[1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000121
3-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000086
3-[1-(4-methoxyphenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000136
3-[1-(4-tert-butylphenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000034
3-[2,5-dimethyl-1-(4-methylphenyl)-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000108
3-[2,5-dimethyl-1-(4-nitrophenyl)-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000048
3-[2,5-dimethyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000108
3-[2,5-dimethyl-1-[4-(naphthalen-2-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.001078
3-[2,5-dimethyl-1-[4-(pyridin-2-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000271
3-[2,5-dimethyl-1-[4-(pyridin-3-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000383
3-[2,5-dimethyl-1-[4-(pyridin-4-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000068
3-[2,5-dimethyl-1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000076
3-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzonitrile
Homo sapiens
pH and temperature not specified in the publication
0.000264
4-((2,5-dioxopyrrolidin-3-ylidene)methyl)phenylthiophene-2-carboxylate
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000096
4-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzonitrile
Homo sapiens
pH and temperature not specified in the publication
0.008915
5-(2-chloro-3-(2-(pyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000211
5-(2-chloro-4-(2-(cyclohexyloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.00105
5-(2-chloro-4-(2-(propan-2-yloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000013
5-(2-chloro-4-(2-cyclohexylethoxy)benzylidene)-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000042
5-(2-chloro-4-(2-cyclopentylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.00454
5-(2-chloro-4-(4-nitrobenzyloxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000081
5-(2-chloro-4-phenbutoxybenzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000178
5-(2-chloro-4-phenethoxybenzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000052
5-(2-chloro-4-phenpropoxybenzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000075
5-(3-chloro-4-((4-(prop-1-en-2-yl)cyclohexyl)methoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000071
5-(3-chloro-4-((5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)oxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.005165
5-(3-chloro-4-(2-(4-methyl-1,3-thiazolidin-5-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.002077
5-(3-chloro-4-(2-(5-ethylpyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000123
5-(3-chloro-4-(2-(5-nitrofuran-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.00002
5-(3-chloro-4-(2-(cyclohexyloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.002738
5-(3-chloro-4-(2-(propan-2-yloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.00444
5-(3-chloro-4-(2-(pyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000084
5-(3-chloro-4-(2-(thiophen-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000099
5-(3-chloro-4-(2-cyclopentylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000132
5-(3-chloro-4-(2-cyclopropylpropyl)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000223
5-(3-chloro-4-(2-thiomorpholine 1,1-dioxideethoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000059
5-(3-chloro-4-(3-(2-nitroethenyl)phenoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.0001
5-(3-chloro-4-(3-nitrophenoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000038
5-(3-chloro-4-(3-phenylpropoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.00093
5-(3-chloro-4-(4-nitrobenzyloxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000048
5-(3-chloro-4-(4-phenylbutoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000009
5-(3-chloro-4-(cyclobutylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000011
5-(3-chloro-4-(cyclopentylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.00002
5-(3-chloro-4-phenylethoxybenzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000052
5-(4-((4-methylcyclohexyl)methoxy)benzylidene) thiazolidine-2,4-dione
Homo sapiens
-
pH 7.5, temperature not specified in the publication
0.000193
5-(4-(1,3-benzodioxol-5-ylmethoxy)-3-chlorobenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000031
5-(4-(2-(thiophen-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 7.5, temperature not specified in the publication
0.00006
5-(4-(2-(thiophen-3-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 7.5, temperature not specified in the publication
0.000116
5-(4-(2-cyclopentylethoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 7.5, temperature not specified in the publication
0.000124
5-(4-(4-(chloromethyl)benzyloxy)benzylidene) thiazolidine-2,4-dione
Homo sapiens
-
pH 7.5, temperature not specified in the publication
0.000487
5-(4-(benzyloxy)-2-chlorobenzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000048
5-(4-(benzyloxy)-3-chlorobenzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000165
5-(4-(bicyclo[2.2.1]hept-2-ylmethoxy)-3-chlorobenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000045
5-(4-(cyclopentylmethoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 7.5, temperature not specified in the publication
0.000051
CT-8
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000038
ethyl 4-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzoate
Homo sapiens
pH and temperature not specified in the publication
0.000383
N,N-diethyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.001358
N-butyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000961
N-cyclopentyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000027
[1-(2-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000012
[1-(3-chlorophenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000019
[1-(3-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000022
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](3-methylpiperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000429
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](3-phenylpiperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.00271
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](4-methylpiperazin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.00304
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](morpholin-4-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000019 - 0.000056
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
0.000383
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](pyrrolidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000048
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][3-(propan-2-yl)piperidin-1-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.000068
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][3-(trifluoromethyl)piperidin-1-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.001524
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][4-(trifluoromethyl)piperidin-1-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.000171
[1-(3-tert-butylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.00022
[1-(4-chlorophenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.00019
[1-(4-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.00019
[1-(4-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000054
[1-(4-tert-butylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.01
[4-(4-methoxyphenyl)piperazin-1-yl](4-[(phenylsulfanyl)methyl]phenyl)methanone
Homo sapiens
-
value above, pH 8, 25°C
0.000019
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000056
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
-
pH 8, 25°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Lee, S.C.; Levine, L.
Prostaglandin metabolism. II. Identification of two 15-hydroxyprostaglandin dehydrogenase types
J. Biol. Chem.
250
548-552
1975
Canis lupus familiaris, Gallus gallus, Homo sapiens, Platyrrhini, Sus scrofa
brenda
Lee, S.C.; Pong, S.S.; Katzen, D.; Wu, K.Y.; Levine, L.
Distribution of prostaglandin E 9-ketoreductase and type I and II 15-hydroxyprostaglandin dehydrogenase in swine kidney medulla and cortex
Biochemistry
14
142-145
1975
Sus scrofa
brenda
Tombach, B.; Kusseler, R.; Schlegel, W.
Purification of human placental prostaglandin 15-hydroxydehydrogenase
J. Chromatogr.
521
231-238
1990
Homo sapiens
brenda
Braithwaite, S.S.; Jabarak, J.
Studies on a 15-hydroxyprostaglandin dehydrogenase from human placenta. Purification and partial characterization
J. Biol. Chem.
250
2315-2318
1975
Homo sapiens
brenda
Jabarak, J.; Braithwaite, S.S.
Kinetic studies on a 15-hydroxyprostaglandin dehydrogenase from human placenta
Arch. Biochem. Biophys.
177
245-254
1976
Homo sapiens
brenda
Saeed, S.A.; Roy, A.C.
Purification of 15-hydroxy prostaglandin dehydrogenase from bovine lung
Biochem. Biophys. Res. Commun.
47
96-102
1972
Bos taurus
brenda
Iijima, Y.; Ueno, T.; Sasagawa, K.; Yamazaki, M.
Inhibition of 15-hydroxyprostaglandin dehydrogenase by papaverine
Biochem. Biophys. Res. Commun.
80
484-489
1978
Canis lupus familiaris, Cavia porcellus, Gallus gallus, Rattus norvegicus, Sus scrofa
brenda
Jung, A.; Schlegel, W.; Jackisch, R.; Friedrich, E.J.; Wendel, A.; Ruckrich, M.F.
15-Hydroxyprostaglandin dehydrogenase from human placenta. 1. Isolation and characterization
Hoppe-Seyler's Z. Physiol. Chem.
356
787-798
1975
Homo sapiens
brenda
Ruckrich, M.F.; Wendel, A.; Schlegel, W.; Jackisch, R.; Jung, A.
15-Hydroxyprostaglandin dehydrogenase from human placenta, II. Steady state kinetics and influence of prostaglandin F2alpha analogues
Hoppe-Seyler's Z. Physiol. Chem.
356
799-809
1975
Homo sapiens
brenda
Bergholte, J.M.; Okita, R.T.
Isolation and properties of lung 15-hydroxyprostaglandin dehydrogenase from pregnant rabbits
Arch. Biochem. Biophys.
245
308-315
1986
Oryctolagus cuniculus
brenda
Krook, M.; Marekov, L.; Jrnvall, H.
Purification and structural characterization of placental NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase. The primary structure reveals the enzyme to belong to the short-chain alcohol dehydrogenase family
Biochemistry
29
738-743
1990
Homo sapiens
brenda
Jabarak, J.
Isolation and properties of an NAD+-dependent 15-hydroxyprostaglandin dehydrogenase from human placenta
Methods Enzymol.
86
126-130
1982
Homo sapiens
brenda
Kung-Chao, D.T.Y.; Tai, H.H.
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase from porcine kidney. II. Kinetic studies
Biochim. Biophys. Acta
614
14-24
1980
Sus scrofa
brenda
Mak, O.T.; Liu, Y.; Tai, H.H.
Purification and characterization of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase from porcine kidney
Biochim. Biophys. Acta
1035
190-196
1990
Sus scrofa
brenda
Hansen, H.S.
Inhibition by indomethacin and aspirin of 15-hydroxyprostaglandin dehydrogenase in vitro
Prostaglandins
8
95-105
1974
Bos taurus
brenda
Schlegel, W.; Demers, L.M.; Hildebrandt-Stark, H.E.; Behrman, H.R.; Greep, R.O.
Partial purification of human placental 15-hydroxy-prostaglandin dehydrogenase: kinetic properties
Prostaglandins
5
417-433
1974
Homo sapiens
brenda
Tai, H.H.
Assay of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase using (15S)-[15-3H]PGE2
Methods Enzymol.
86
131-135
1982
Sus scrofa
brenda
Sakuma, S.; Fujimoto, Y.; Hikita, E.; Okano, Y.; Yamamoto, I.; Fujita, T.
Effects of metal ions on 15-hydroxy prostaglandin dehydrogenase activity in rabbit kidney cortex
Prostaglandins
40
507-514
1990
Oryctolagus cuniculus
brenda
Treissman, D.; Smith, G.N.; Patrick, J.; Brien, J.F.
Effect of ethanol on 15-hydroxyprostaglandin dehydrogenase activity in the brain stem of the near-term fetal sheep
Dev. Pharmacol. Ther.
16
48-52
1991
Ovis aries
brenda
Xun, C.Q.; Ensor, C.M.; Tai, H.H.
Regulation of synthesis and activity of NAD+-dependent 15-hydroxy-prostaglandin dehydrogenase (15-PGDH) by dexamethasone and phorbol ester in human erythroleukemia (HEL) cells
Biochem. Biophys. Res. Commun.
177
1258-1265
1991
Homo sapiens
brenda
Jarabak, J.
Polycyclic aromatic hydrocarbon quinones may be either substrates for or irreversible inhibitors of the human placental NAD-linked 15-hydroxyprostaglandin dehydrogenase
Arch. Biochem. Biophys.
292
239-243
1992
Homo sapiens
brenda
Mibe, M.; Nagai, K.; Oshige, T.; Mori, N.
Endogenous inhibitors of human placental prostaglandin dehydrogenase
Prostaglandins Leukot. Essent. Fatty Acids
46
241-245
1992
Homo sapiens
brenda
Chavan, A.J.; Ensoe, C.M.; Wu, P.; Haley, B.E.; Tai, H.H.
Photoaffinity labeling of human placental NAD+-linked 15-hydroxyprostaglandin dehydrogenase with [alpha-32]2N3NAD+
J. Biol. Chem.
268
16437-16442
1993
Homo sapiens
brenda
Hhl, W.; Stahl, B.; Mundkowski, R.; Hofmann, U.; Meese, C.O.; Kuhlmann, U.; Schlegel, W.
Mass determination of 15-hydroxyprostaglandin dehydrogenase from human placenta and kinetic studies with (5Z,8E,10E,12S)-12-hydroxy-5,8,10,-heptadecatrienoic acid as substrate
Eur. J. Biochem.
214
67-73
1993
Homo sapiens
brenda
Sakuma, S.; Fujimoto, Y.; Nakagawa, H.; Hachiki, S.; Nishida, H.; Fujita, T.
Effect of 13-hydroperoxyoctadecadienoic acid on 15-hydroxy prostaglandin dehydrogenase activity in rabbit kidney cortex
Prostaglandins
46
157-165
1993
Oryctolagus cuniculus
brenda
Ensoe, C.M.; Tai, H.H.
Bacterial expression and site-directed mutagenesis of two critical residues (tyrosine-151 and lysine-155) of human placental NAD+-dependent 15-hydroxyprostaglandin dehydrogenase
Biochim. Biophys. Acta
1208
151-156
1994
Homo sapiens
brenda
Okita, R.T.; Okita, J.R.
Prostaglandin-metabolizing enzymes during pregnancy: characterization of NAD+-dependent prostaglandin dehydrogenase, carbonyl reductase, and cytochrome P450-dependent prostaglandin omega-hydroxylase
CRC Crit. Rev. Biochem.
31
101-126
1996
Bos taurus, Oryctolagus cuniculus, Homo sapiens, Rattus norvegicus, Sus scrofa
brenda
Tong, M.; Tai, H.H.
Induction of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells
Biochem. Biophys. Res. Commun.
276
77-81
2000
Homo sapiens
brenda
Fujimori, K.; Okada, T.; Urade, Y.
Expression of NADP(+)-Dependent 15-Hydroxyprostaglandin Dehydrogenase mRNA in Monkey Ocular Tissues and Characterization of Its Recombinant Enzyme
J. Biochem.
131
383-389
2002
Macaca fascicularis
brenda
Tai, H.H.; Ensor, C.M.; Zhou, H.; Yan, F.
Structure and function of human NAD+-linked 15-hydroxyprostaglandin dehydrogenase
Adv. Exp. Med. Biol.
507
245-250
2002
Homo sapiens
brenda
Cho, H.; Tai, H.H.
Thiazolidinediones as a novel class of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors
Arch. Biochem. Biophys.
405
247-251
2002
Homo sapiens
brenda
Cho, H.; Oliveira, M.A.; Tai, H.H.
Critical residues for the coenzyme specificity of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase
Arch. Biochem. Biophys.
419
139-146
2003
Homo sapiens
brenda
Cho, H.; Hamza, A.; Zhan, C.G.; Tai, H.H.
Key NAD+-binding residues in human 15-hydroxyprostaglandin dehydrogenase
Arch. Biochem. Biophys.
433
447-453
2005
Homo sapiens
brenda
Tong, M.; Tai, H.H.
15-Hydroxyprostaglandin dehydrogenase can be induced by dexamethasone and other glucocorticoids at the therapeutic level in A549 human lung adenocarcinoma cells
Arch. Biochem. Biophys.
435
50-55
2005
Homo sapiens
brenda
Cho, H.; Tai, H.H.
Threonine 11 of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase may interact with NAD(+) during catalysis
Prostaglandins
66
505-509
2002
Homo sapiens
brenda
Cho, H.; Tai, H.H.
Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents
Prostaglandins
67
461-465
2002
Homo sapiens
brenda
Otani, T.; Yamaguchi, K.; Scherl, E.; Du, B.; Tai, H.H.; Greifer, M.; Petrovic, L.; Daikoku, T.; Dey, S.K.; Subbaramaiah, K.; Dannenberg, A.J.
Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha
Am. J. Physiol.
290
G361-G368
2006
Homo sapiens
brenda
Tong, M.; Ding, Y.; Tai, H.H.
Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells
Biochem. Pharmacol.
72
701-709
2006
Homo sapiens
brenda
Hamza, A.; Cho, H.; Tai, H.H.; Zhan, C.G.
Understanding human 15-hydroxyprostaglandin dehydrogenase binding with NAD+ and PGE2 by homology modeling, docking and molecular dynamics simulation
Bioorg. Med. Chem.
13
4544-4551
2005
Homo sapiens
brenda
Mann, J.R.; Backlund, M.G.; Buchanan, F.G.; Daikoku, T.; Holla, V.R.; Rosenberg, D.W.; Dey, S.K.; DuBois, R.N.
Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression
Cancer Res.
66
6649-6656
2006
Homo sapiens
brenda
Wolf, I.; OKelly, J.; Rubinek, T.; Tong, M.; Nguyen, A.; Lin, B.T.; Tai, H.H.; Karlan, B.Y.; Koeffler, H.P.
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer
Cancer Res.
66
7818-7823
2006
Homo sapiens
brenda
Ding, Y.; Tong, M.; Liu, S.; Moscow, J.A.; Tai, H.H.
NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer
Carcinogenesis
26
65-72
2005
Homo sapiens
brenda
Tong, M.; Ding, Y.; Tai, H.H.
Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells
Carcinogenesis
27
2170-2179
2006
Homo sapiens
brenda
Tai, H.H.; Cho, H.; Tong, M.; Ding, Y.
NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions
Curr. Pharm. Des.
12
955-962
2006
Homo sapiens
brenda
Backlund, M.G.; Mann, J.R.; Holla, V.R.; Buchanan, F.G.; Tai, H.H.; Musiek, E.S.; Milne, G.L.; Katkuri, S.; DuBois, R.N.
15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer
J. Biol. Chem.
280
3217-3223
2005
Homo sapiens, Mus musculus
brenda
Giannoulias, D.; Haluska, G.J.; Gravett, M.G.; Sadowsky, D.W.; Challis, J.R.; Novy, M.J.
Localization of prostaglandin H synthase, prostaglandin dehydrogenase, corticotropin releasing hormone and glucocorticoid receptor in rhesus monkey fetal membranes with labor and in the presence of infection
Placenta
26
289-297
2005
Macaca mulatta
brenda
Myung, S.J.; Rerko, R.M.; Yan, M.; Platzer, P.; Guda, K.; Dotson, A.; Lawrence, E.; Dannenberg, A.J.; Lovgren, A.K.; Luo, G.; Pretlow, T.P.; Newman, R.A.; Willis, J.; Dawson, D.; Markowitz, S.D.
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis
Proc. Natl. Acad. Sci. USA
103
12098-12102
2006
Mus musculus, Mus musculus C57/BL6J
brenda
Quidville, V.; Segond, N.; Lausson, S.; Frenkian, M.; Cohen, R.; Jullienne, A.
15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line
Prostaglandins Other Lipid Mediat.
81
14-30
2006
Homo sapiens
brenda
Parent, M.; Madore, E.; MacLaren, L.A.; Fortier, M.A.
15-Hydroxyprostaglandin dehydrogenase in the bovine endometrium during the oestrous cycle and early pregnancy
Reproduction
131
573-582
2006
Bos taurus (Q309F3), Bos taurus
brenda
Yao, B.; Xu, J.; Harris, R.C.; Zhang, M.Z.
Renal localization and regulation of 15-hydroxyprostaglandin dehydrogenase
Am. J. Physiol. Renal Physiol.
294
F433-F439
2008
Mus musculus, Rattus norvegicus
brenda
Yang, L.; Amann, J.M.; Kikuchi, T.; Porta, R.; Guix, M.; Gonzalez, A.; Park, K.H.; Billheimer, D.; Arteaga, C.L.; Tai, H.H.; DuBois, R.; Carbone, D.P.; Johnson, D.H.
Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer
Cancer Res.
67
5587-5593
2007
Homo sapiens
brenda
Huang, G.; Eisenberg, R.; Yan, M.; Monti, S.; Lawrence, E.; Fu, P.; Walbroehl, J.; Loewenberg, E.; Golub, T.; Merchan, J.; Tenen, D.G.; Markowitz, S.D.; Halmos, B.
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer
Cancer Res.
68
5040-5048
2008
Homo sapiens
brenda
Michelet, J.F.; Colombe, L.; Gautier, B.; Gaillard, O.; Benech, F.; Pereira, R.; Boulle, C.; Dalko-Csiba, M.; Rozot, R.; Neuwels, M.; Bernard, B.A.
Expression of NAD(+) dependent 15-hydroxyprostaglandin dehydrogenase and protection of prostaglandins in human hair follicle
Exp. Dermatol.
17
821-828
2008
Homo sapiens (P15428), Homo sapiens
brenda
Chou, W.L.; Chuang, L.M.; Chou, C.C.; Wang, A.H.; Lawson, J.A.; FitzGerald, G.A.; Chang, Z.F.
Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E2 catabolism in regulation of peroxisome proliferator-activated receptor gamma activation
J. Biol. Chem.
282
18162-18172
2007
Mus musculus
brenda
Pham, H.; Eibl, G.; Vincenti, R.; Chong, B.; Tai, H.H.; Slice, L.W.
15-Hydroxyprostaglandin dehydrogenase suppresses K-RasV12-dependent tumor formation in Nu/Nu mice
Mol. Carcinog.
47
466-477
2008
Rattus norvegicus, Rattus norvegicus (O08699)
brenda
Roizen, J.D.; Asada, M.; Tong, M.; Tai, H.H.; Muglia, L.J.
Preterm birth without progesterone withdrawal in 15-hydroxyprostaglandin dehydrogenase hypomorphic mice
Mol. Endocrinol.
22
105-112
2008
Mus musculus
brenda
Hazra, S.; Batra, R.K.; Tai, H.H.; Sharma, S.; Cui, X.; Dubinett, S.M.
Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase
Mol. Pharmacol.
71
1715-1720
2007
Homo sapiens
brenda
Uppal, S.; Diggle, C.P.; Carr, I.M.; Fishwick, C.W.; Ahmed, M.; Ibrahim, G.H.; Helliwell, P.S.; Latos-Biele?ska, A.; Phillips, S.E.; Markham, A.F.; Bennett, C.P.; Bonthron, D.T.
Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy
Nat. Genet.
40
789-793
2008
Homo sapiens
brenda
Tai, H.H.; Tong, M.; Ding, Y.
15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer
Prostaglandins Other Lipid Mediat.
83
203-208
2007
Homo sapiens
brenda
Rizek, R.M.; Watson, C.S.; Keating, S.; Tai, H.; Challis, J.R.; Bocking, A.D.
15-Hydroxyprostaglandin dehydrogenase protein expression in human fetal membranes with and without subclinical inflammation
Reprod. Sci.
14
260-269
2007
Homo sapiens
brenda
Miyaki, A.; Yang, P.; Tai, H.H.; Subbaramaiah, K.; Dannenberg, A.J.
Bile acids inhibit NAD+-dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes
Am. J. Physiol. Gastrointest. Liver Physiol.
297
G559-G566
2009
Homo sapiens
brenda
Chi, X.; Freeman, B.M.; Tong, M.; Zhao, Y.; Tai, H.H.
15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells
Arch. Biochem. Biophys.
487
139-145
2009
Homo sapiens
brenda
Hughes, D.; Otani, T.; Yang, P.; Newman, R.A.; Yantiss, R.K.; Altorki, N.K.; Port, J.L.; Yan, M.; Markowitz, S.D.; Mazumdar, M.; Tai, H.H.; Subbaramaiah, K.; Dannenberg, A.J.
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer
Cancer Prev. Res. (Phila.)
1
241-249
2008
Homo sapiens
brenda
Backlund, M.G.; Mann, J.R.; Holla, V.R.; Shi, Q.; Daikoku, T.; Dey, S.K.; DuBois, R.N.
Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and Snail in colorectal cancer
Cancer Res.
68
9331-9337
2008
Homo sapiens
brenda
Tariq, M.; Azeem, Z.; Ali, G.; Chishti, M.S.; Ahmad, W.
Mutation in the HPGD gene encoding NAD+ dependent 15-hydroxyprostaglandin dehydrogenase underlies isolated congenital nail clubbing (ICNC)
J. Med. Genet.
46
14-20
2009
Homo sapiens
brenda
Celis, J.E.; Gromov, P.; Cabezon, T.; Moreira, J.M.; Friis, E.; Jirstroem, K.; Llombart-Bosch, A.; Timmermans-Wielenga, V.; Rank, F.; Gromova, I.
15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma
Mol. Cell. Proteomics
7
1795-1809
2008
Homo sapiens (P15428)
brenda
Wei, C.; Zhu, P.; Shah, S.J.; Blair, I.A.
15-oxo-Eicosatetraenoic acid, a metabolite of macrophage 15-hydroxyprostaglandin dehydrogenase that inhibits endothelial cell proliferation
Mol. Pharmacol.
76
516-525
2009
Homo sapiens
brenda
Wu, Y.; Tai, H.H.; Cho, H.
Synthesis and SAR of thiazolidinedione derivatives as 15-PGDH inhibitors
Bioorg. Med. Chem.
18
1428-1433
2010
Homo sapiens
brenda
Liu, Z.; Wang, X.; Lu, Y.; Du, R.; Luo, G.; Wang, J.; Zhai, H.; Zhang, F.; Wen, Q.; Wu, K.; Fan, D.
15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human gastric cancer
Cancer Biol. Ther.
10
780-787
2010
Homo sapiens
brenda
Chi, X.; Tai, H.H.
Interleukin-4 up-regulates 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in human lung cancer cells
Exp. Cell Res.
316
2251-2259
2010
Homo sapiens
brenda
Wu, Y.; Karna, S.; Choi, C.H.; Tong, M.; Tai, H.H.; Na, D.H.; Jang, C.H.; Cho, H.
Synthesis and biological evaluation of novel thiazolidinedione analogues as 15-hydroxyprostaglandin dehydrogenase inhibitors
J. Med. Chem.
54
5260-5264
2011
Homo sapiens
brenda
Thill, M.; Fischer, D.; Kelling, K.; Hoellen, F.; Dittmer, C.; Hornemann, A.; Salehin, D.; Diedrich, K.; Friedrich, M.; Becker, S.
Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer
J. Steroid Biochem. Mol. Biol.
121
387-390
2010
Homo sapiens
brenda
Lu, D.; Han, C.; Wu, T.
15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARgamma-mediated activation of p21(WAF1/Cip1.)
Oncogene
33
1101-1112
2013
Homo sapiens
brenda
Niesen, F.; Schultz, L.; Jadhav, A.; Bhatia, C.; Guo, K.; Maloney, D.; Pilka, E.; Wang, M.; Oppermann, U.; Heightman, T.; Simeonov, A.
High-affinity inhibitors of human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase: mechanisms of inhibition and structure-activity relationships
PLoS ONE
5
e13719
2010
Homo sapiens
brenda
Welsh, T.; Paul, J.; Palliser, H.K.; Tabatabaee, H.; Hirst, J.; Mesiano, S.; Zakar, T.
15-Hydroxyprostaglandin dehydrogenase expression and localization in guinea pig gestational tissues during late pregnancy and parturition
Reprod. Sci.
19
1099-1109
2012
Sus scrofa
brenda
Liu, Y.; Jia, Z.; Sun, Y.; Zhou, L.; Downton, M.; Chen, R.; Zhang, A.; Yang, T.
Postnatal regulation of 15-hydroxyprostaglandin dehydrogenase in the rat kidney
Am. J. Physiol. Renal Physiol.
307
F388-F395
2014
Rattus norvegicus
brenda
Gram, A.; Buechler, U.; Boos, A.; Hoffmann, B.; Kowalewski, M.P.
Biosynthesis and degradation of canine placental prostaglandins: prepartum changes in expression and function of prostaglandin F2?-synthase (PGFS, AKR1C3) and 15-hydroxyprostaglandin dehydrogenase (HPGD)
Biol. Reprod.
89
2-2
2013
Canis lupus familiaris (E2QX67), Canis lupus familiaris
brenda
Duveau, D.Y.; Yasgar, A.; Wang, Y.; Hu, X.; Kouznetsova, J.; Brimacombe, K.R.; Jadhav, A.; Simeonov, A.; Thomas, C.J.; Maloney, D.J.
Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors
Bioorg. Med. Chem. Lett.
24
630-635
2014
Homo sapiens (P15428), Homo sapiens
brenda
Choi, D.; Piao, Y.L.; Wu, Y.; Cho, H.
Control of the intracellular levels of prostaglandin E2 through inhibition of the 15-hydroxyprostaglandin dehydrogenase for wound healing
Bioorg. Med. Chem.
21
4477-4484
2013
Homo sapiens (P15428)
brenda
Castro-Sanchez, L.; Agra, N.; Llorente Izquierdo, C.; Motino, O.; Casado, M.; Bosca, L.; Martin-Sanz, P.
Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma
Int. J. Biochem. Cell Biol.
45
2501-2511
2013
Homo sapiens (P15428), Homo sapiens
brenda
Lu, D.; Han, C.; Wu, T.
15-hydroxyprostaglandin dehydrogenase-derived 15-keto-prostaglandin E2 inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor-gamma, SMAD2/3, and TAP63 proteins
J. Biol. Chem.
288
19484-19502
2013
Homo sapiens (P15428), Homo sapiens
brenda
Kim, H.J.; Lee, S.; Lee, H.Y.; Won, H.; Chang, S.H.; Nah, S.S.
15-hydroxyprostaglandin dehydrogenase is upregulated by hydroxychloroquine in rheumatoid arthritis fibroblast-like synoviocytes
Mol. Med. Rep.
12
4141-4148
2015
Homo sapiens (P15428), Homo sapiens
brenda
Kim, H.; Lee, H.; Lim, K.; Surh, Y.; Na, H.
15-Deoxy-DELTA12,14-prostaglandin J2 induces expression of 15-hydroxyprostaglandin dehydrogenase through Elk-1 activation in human breast cancer MDA-MB-231 cells
Mutat. Res.
768
6-15
2014
Homo sapiens (P15428), Homo sapiens
brenda
Sola-Villa, D.; Dilme, J.F.; Rodriguez, C.; Soto, B.; Vila, L.; Escudero, J.R.; Martinez-Gonzalez, J.; Camacho, M.
Expression and cellular localization of 15-hydroxy-prostaglandin-dehydrogenase in abdominal aortic aneurysm
PLoS ONE
10
e0136201
2015
Homo sapiens (P15428), Homo sapiens
brenda
Lee, J.; Zhong, X.; Lee, J.; Surh, Y.; Na, H.
15-Keto prostaglandin E2 induces heme oxygenase-1 expression through activation of Nrf2 in human colon epithelial CCD 841 CoN cells
Arch. Biochem. Biophys.
679
108162
2020
Homo sapiens (P15428), Homo sapiens
brenda
Yao, L.; Chen, W.; Song, K.; Han, C.; Gandhi, C.R.; Lim, K.; Wu, T.
15-hydroxyprostaglandin dehydrogenase (15-PGDH) prevents lipopolysaccharide (LPS)-induced acute liver injury
PLoS ONE
12
e0176106
2017
Mus musculus (Q8VCC1), Mus musculus
brenda